Karyopharm Therapeutics is an innovation-driven pharmaceutical company based in Natick, MA, dedicated to discovering, developing, and commercializing medicines to enhance the lives of patients battling cancer and other major diseases. With a focus on SINE (Selective Inhibitor of Nuclear Export) technology, Karyopharm aims to address the fundamental mechanisms of oncogenesis, transforming healthy cells into cancer cells.
With a robust pipeline of four unique drug candidates in clinical development, Karyopharm is at the forefront of developing targeted therapies for patients with both hematologic and solid tumors. Committed to putting patients at the center of their mission, Karyopharm's ongoing clinical trials and dedication to innovation underscore their relentless pursuit of advancing important new treatments for those in need.
Generated from the website